A Virginia law firm has asked a Massachusetts federal judge to reconsider consolidating in federal court the cases of plaintiffs allegedly injured after their injection with steroids tainted with fungus.
The New England Compounding Center produced an injectable steroid, methylprednisolone acetate, which became infected with fungus and led to a multi-state breakout of fatal meningitis. The company filed for bankruptcy in December 2012, following the breakout. Federal multidistrict litigation is also pending.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
